| Macrocycle Diary's New Entry: Ensemble Deal with Boehringer | | By entering a potential $186 million research pact with Ensemble Therapeutics Inc. for synthetic macrocycles, Boehringer Ingelheim GmbH became the latest to place its bet on a newish, challenging approach that could combine the all-in-all pill possibility of small molecules with the biological bull's-eye talent of large ones. Find out the details. |  |
| Health Care & Policy |  |  | | - BioMarin's experimental MPS IVA drug meets main endpoint in trial
A late-stage trial found that BioMarin Pharmaceutical's enzyme replacement therapy GALNS, or N-acetylgalactosamine-6 sulfatase, helped patients with mucopolysaccharidosis IVA walk 22.5 meters farther in six minutes, the primary goal of the study, compared with placebo. BioMarin plans to apply for regulatory approval next year. Bloomberg (11/5), BioWorld Online (free registration) (11/5)       - Amgen's cholesterol drug performs well in Phase II study
Patients with heterozygous familial hypercholesterolemia who received Amgen's investigational drug AMG145 plus statins saw their LDL, or "bad," cholesterol levels drop by up to 55% compared with patients who took a placebo during a midstage trial. AMG145 is designed to target the PCSK9 protein, which stops the body from eliminating LDL cholesterol from the bloodstream. Reuters (11/5) - Pharma takes risk with vulnerable "product shots"
 Interest in finding the next blockbuster drug prompts major pharmaceutical firms to risk significant amounts of money and resources in huge, individual development programs, or "product shots," Forbes contributor David Shaywitz writes. Drugmakers have a better chance of success with numerous small drug development programs, he writes. Forbes (11/5) - Stem cell treatment shows promise for sperm function
A study in the journal Cell Stem Cell found that sperm-producing stem cells taken from monkeys before chemotherapy can be returned after treatment to improve reproductive function. The method resulted in working sperm from three out of five prepubescent monkeys and nine out of 12 mature monkeys. BBC (11/1) | Company & Financial News | | | | | Global Developments | | | | - U.K. allots $16M for creation of synthetic biology center
The U.K. plans to allocate $16 million over five years to establish an Innovation and Knowledge Centre in Synthetic Biology to aid the development and market launch of synthetic biology technologies. The Biotechnology and Biological Sciences Research Council, which will support the funding program along with the Technology Strategy Board and the Engineering and Physical Sciences Research Council, is inviting institutions to submit their proposals. GenomeWeb Daily News (free registration) (11/2)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | - Scientists develop tomato that could fight heart disease
Scientists from the University of California at Los Angeles have developed a tomato that produces a peptide that imitates the main protein in good cholesterol. Mice fed with the modified tomatoes had less inflammation and atherosclerosis. "We have found a new and practical way to make a peptide that acts like the main protein in good cholesterol, but is many times more effective and can be delivered by eating the plant," said Dr. Alan Fogelman, head of the department of medicine at UCLA. HealthDay News (11/5), Daily Express (London) (11/6) | Industrial & Environmental | | | | - Researchers find quick way to convert algae into biocrude
Researchers at the University of Michigan have found a way to turn marine algae into biocrude by "pressure cooking" it in intense heat for as little as one minute. "My guess is that the reactions that produce biocrude are actually much faster than previously thought," said Phil Savage, a chemical engineering professor. The researchers emphasized the need for further study. DomesticFuel.com (11/2) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | It's impossible to move, to live, to operate at any level without leaving traces, bits, seemingly meaningless fragments of personal information."
--William Gibson,
American-Canadian author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, November 05, 2012
- Friday, November 02, 2012
- Thursday, November 01, 2012
- Wednesday, October 31, 2012
- Tuesday, October 30, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment